多发性内分泌腺瘤病综合征中肽受体放射性核素治疗的安全性与疗效:单中心经验
单中心回顾性分析15例多发性内分泌腺瘤病(MEN)综合征合并晚期神经内分泌肿瘤(NET)患者,接受177Lu-DOTATATE治疗(每周期5.5-7.4 GBq,每8-12周一次,最多4周期)。80%患者出现1/2级不良事件,以白细胞减少最常见;客观缓解率43%,疾病控制率86%,中位无进展生存期32.6个月(95%CI:14.7-未达到),估计5年总生存率76.2%(95%CI:52.1-100)。
要点
- 177Lu-DOTATATE治疗MEN综合征相关晚期NET,80%患者出现1/2级不良事件,白细胞减少最常见。
- 6例(43%)达部分缓解,6例(86%)疾病控制,2例(14%)治疗期间进展。
- 中位无进展生存期32.6个月(95%CI:14.7-未达到),估计5年总生存率76.2%。
核心结论
- 177Lu-DOTATATE是MEN综合征晚期NET安全有效的治疗选择,但需大样本多中心前瞻性研究。
研究设计与样本
- 单中心回顾性分析15例MEN综合征合并晚期NET转诊行PRRT的患者。
- 给予最多4周期177Lu-DOTATATE(5.5-7.4 GBq/周期),每8-12周一次。
- 不良事件采用CTCAE v5评估,最佳疗效采用RECIST 1.1评估,随访计算PFS和OS。
主要发现
- 15例患者中位年龄36岁(IQR:32-49),14例MEN-1综合征,1例MEN-2综合征。
- 13例MEN-1综合征患者中,胃肠胰NET最常见,多灶原发最常见(n=7);1例胸腺类癌;所有患者均有甲状旁腺功能亢进,6例有垂体腺瘤。
- 共53周期177Lu-DOTATATE(范围:1-4),中位累积活度27.8 GBq。
- 12例(80%)出现1/2级不良事件,最常见为白细胞减少。
- 6例部分缓解(ORR 43%),6例疾病稳定(DCR 86%),2例(14%)PRRT期间进展,1例失访。
关键数值与推荐
- PRRT在晚期NET中获推荐和批准,但在MEN综合征中的数据缺乏。
- 177Lu-DOTATATE给药方案:每周期5.5-7.4 GBq,每8-12周一次,最多4周期。
- 不良事件分级采用CTCAE v5,疗效评估采用RECIST 1.1。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需大样本多中心前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Peptide receptor radionuclide therapy (PRRT) is recommended and approved in advanced neuroendocrine tumors (NETs). There is a lack of data on the utility of PRRT in multiple endocrine neoplasia (MEN) syndrome. This study explores the utility of PRRT in MEN syndrome patients with inoperable/metastatic NETs. METHODS: A single-center retrospective analysis of MEN syndrome patients with advanced NETs referred for PRRT was done. Upto 4 cycles of 177 Lu-DOTATATE (5.5-7.4 GBq/cycle) were administered every 8-12 weeks. Treatment-related adverse events were assessed using CTCAE v5. The best response to PRRT was evaluated using RECIST 1.1. Follow-up was done to calculate the progression-free survival (PFS) and overall survival (OS). RESULTS: The data of 15 patients with a median age of 36 years (IQR: 32-49) was analyzed. Fourteen patients had MEN-1 syndrome, and 1 had MEN-2 syndrome. Thirteen patients with MEN-1 syndrome had gastroenteropancreatic (GEP) NET, with the multifocal primary as the most common finding (n=7). One patient had thymic carcinoid. All patients had hyperparathyroidism, while 6 had pituitary adenoma. Fifty-three cycles of 177 Lu-DOTATATE (range: 1-4) were administered with a median cumulative activity of 27.8 GBq. Twelve patients (80%) showed grade 1/2 adverse events, with leukopenia being the most common. Six patients achieved partial response (43% ORR), 6 showed stable disease (86% DCR), 2 (14%) showed disease progression during PRRT, while 1 patient was lost to follow-up. The median PFS was 32.6 months (95% CI: 14.7-not reached) with an estimated 1- and 5-year PFS rate of 86.2% (95% CI: 68-100) and 46.3% (95% CI: 13-80), and estimated 5-year OS rate of 76.2% (95% CI: 52.1-100). CONCLUSIONS: 177 Lu-DOTATATE is a safe and effective treatment option for advanced NETs in MEN syndrome. However, large-sized multicentric prospective studies are required.
引用
- Aggarwal P, Satapathy S, Kaur G, et al. Safety and Efficacy of Peptide Receptor Radionuclide Therapy in Multiple Endocrine Neoplasia Syndrome: A Single-center Experience. Clin Nucl Med. 2025. PMID: 40392141. doi:10.1097/RLU.0000000000005891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。